All News from Accelerate Diagnostics

All News

Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015

Aug 05, 2015 — Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM […]

Continue reading ›

Accelerate Diagnostics Achieves CE-IVD Milestone for ID/AST System and ID/AST Blood Culture Assay

Jun 30, 2015 — Accelerate Diagnostics, Inc., announced today its declaration of conformity to the European In VitroDiagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. The Accelerate ID/AST System is a diagnostic platform providing rapid identification and antimicrobial susceptibility testing of serious infections. In addition, […]

Continue reading ›

Accelerate Diagnostics Announces New Leadership Appointments

Apr 17, 2015 — Accelerate Diagnostics, Inc., an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it has appointed Ron Price as Senior Vice President and Head of Commercial Operations for theAmericas. Mr. Price will replace Pete Bantock who is moving to the newly created position of Chief […]

Continue reading ›

Accelerate Diagnostics Names Juan Martin as Head of Europe, Middle East and Africa

Mar 23, 2015 — Accelerate Diagnostics, Inc., an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it has named Juan Martin as Executive Vice President and Head of Europe, Middle East and Africa(EMEA). Martin brings an exceptional track record of success in leading large, global healthcare diagnostics businesses. […]

Continue reading ›

Accelerate Diagnostics Achieves ISO 13485 Certification and Initial Installations of Accelerate ID/AST System

Mar 16, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it received ISO 13485:2003 certification for its quality management system and began manufacturing and installing GMP compliant systems at select study sites. The company will seek FDA clearance of the Accelerate […]

Continue reading ›

Accelerate Diagnostics to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Jan 07, 2015 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January […]

Continue reading ›

Accelerate Diagnostics Announces Research Collaboration With CDC Laboratory for Early Detection of Antibiotic-Resistant Biothreat Agents

Nov 03, 2014 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms, today announced that it has entered into a research collaboration with the Rapid Antimicrobial Susceptibility Testing Laboratory at the U.S. Centers for Disease Control and Prevention (CDC) to develop tests for the rapid analysis […]

Continue reading ›

Accelerate Diagnostics Supports Drug Stewardship and Early Detection in The President’s Initiative to Combat Antibiotic-Resistant Bacteria

Sep 24, 2014 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms, today commended the Obama Administration’s actions to combat antibiotic-resistant bacteria, and underscored two areas of critical importance. “Antibiotic stewardship in healthcare settings is essential for fighting these life-threatening infections and reducing the significant cost […]

Continue reading ›

Accelerate Diagnostics Announces Final Results of Rights Offering

May 02, 2014 — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider investors, together with funds committed through the related standby commitments, the company raised $45,000,000 from the rights offering. Stockholders subscribed for a total of 1,517,880 shares of the company’s common stock […]

Continue reading ›

Accelerate Diagnostics Commences Rights Offering

Apr 07, 2014 — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that it has commenced a $45,000,000 rights offering to fund its product commercialization efforts. Under the terms of the rights offering, the company is distributing, at no […]

Continue reading ›